Methylenetetrahydrofolate reductase (MTHFR): A novel target for cancer therapy

Current Pharmaceutical Design

Volumn 14, Issue 11, 2008, Pages 1143-1150

  Stankova, J ^a   Lawrance, A K ^a   Rozen, R ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Apoptosis; Folate; Homocysteine; Methionine; Methylation; Methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMINOPTERIN; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; AZACITIDINE; CARMUSTINE; CISPLATIN; DNA METHYLTRANSFERASE INHIBITOR; EDATREXATE; ETHIONINE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; MACROGOL; METHIONINE; METHIONINE GAMMA LYASE; METHOTREXATE; MG 98; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PEMETREXED; PIRITREXIM; PURINE ANTAGONIST; PYRIMIDINE ANTAGONIST; RALTITREXED; RECOMBINANT METHIONINE GAMMA LYASE; RG 108; TRIMETREXATE; UNINDEXED DRUG; ZEBULARINE; ANTISENSE OLIGONUCLEOTIDE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA METHYLATION; DNA SYNTHESIS INHIBITION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; EXON; FOLATE METABOLISM; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LIVER TOXICITY; LUNG CANCER; LYMPHADENOPATHY; MONOTHERAPY; NEOPLASM; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN RESTRICTION; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; SPLENOMEGALY; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG ANTAGONISM; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FOLIC ACID; HUMANS; METHIONINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 45549084604     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784246171     Document Type: Review

References (98)

1. Melse-Boonstra A, de Bree A, Verhoef P, Bjorke-Monsen AL, Verschuren WM. Dietary monoglutamate and polyglutamate folate are associated with plasma folate concentrations in Dutch men and women aged 20-65 years. J Nutr 2002; 132: 1307-12.
2. McKillop Di, Pentieva K, Daly D, McPartlin JM, Hughes J, Strain JJ, et al. The effect of different cooking methods on folate retention in various foods that are amongst the major contributors to folate intake in the UK diet. Br J Nutr 2002; 88: 681-8.
3. Murphy M, Keating M, Boyle P, Weir DG, Scott JM. The elucidation of the mechanism of folate catabolism in the rat. Biochem Biophys Res Commun 1976; 71: 1017-24.
4. Moran RG. Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: An overview. Semin Oncol 1999; 26: 24-32.
5. Lu Y, Low PS. Folate-mediated delivery of macromolecular anti-cancer therapeutic agents. Adv Drug Deliv Rev 2002; 54: 675-93.
6. Farber S. Some observations on the effect or folic acid antagonists on acute leukemia and other forms of incurable cancer Blood 1949; 4: 160-7.
7. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1948; 238: 787-93.
8. Hertz R, Li MC, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956; 93: 361-6.
9. Takimoto CH. New antifolates: Pharmacology and clinical applications. Oncologist 1996; 1: 68-81.
10. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003; 22: 7431-57.
11. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006; 24: 37-77.
12. Rhee MS, Coward JK, Galivan J. Depletion of 5,10-methylenetetrahydrofolate and 10-formyltetrahydrofolate by methotrexate in cultured hepatoma cells. Mol Pharmacol 1992; 42: 909-16.
13. Calvert H. An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol 1999; 26: 3-10.
14. Allegra, CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985; 260: 9720-6.
15. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimodazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985; 82: 4881-5.
16. Chu E, Drake JC, Boarman D, Baram J, Allegra CJ. Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. J Biol Chem 1990; 265: 8470-8.
17. Haller DG. Trimetrexate: Experience with solid tumors. Semin Oncol 1997; 24: S18-71-S18-76.
18. Marshall JL, DeLap RJ. Clinical pharmacokinetics and pharmacology of trimetrexate. Clin Pharmacokinet 1994; 26: 190-200.
19. Grant SC, Kris MG, Young CW, Sirotnak FM. Edatrexate, an antifolate with antitumor activity: A review. Cancer Invest 1993; 11: 36-45.
20. Sigel CW, Macklin AW, Woolley JL Jr, Johnson NW, Collier MA, Blum MR, et al. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. NCI Monogr 1987: 111-20.
21. Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL, Pinedo HM. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 2000, 36: 916-24.
22. Backus HH, Pinedo HM, Wouters B, Kuiper CM, Jansen G, van Groeningen CJ, et al. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol Res 2000; 12: 231-9.
23. Ferguson PJ, Collins O, Dean NM, DeMoor J, Li CS, Vincent MD, et al. Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol 1999 127: 1777-86.
24. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.
25. Wright JE, Dreyfuss A, el-Magharbel I, Trites D, Jones SM, Holden SA, et al. Selective expansion of 5,10-methylenetetrahydro-folate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 1989; 49: 2592-6.
26. Takimoto CH. Antifolates in clinical development. Semin Oncol 1997; 24: S18-40-S18-51.
27. Gmeiner WH. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 2005; 12: 191-202.
28. Cao S, Bhattacharya A, Durrani FA, Fakih M. Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Expert Opin Pharmacother 2006; 7: 687-703.
29. Benepal TS, Judson I. ZD39331: Discovery to clinical development Anticancer Drugs 2005; 16: 1-9.
30. Niculescu-Duvaz I. Thymitaq (Zarix). Curr Opin Investig Drugs 2001; 2: 693-705.
31. Koda RT, Garcia AA, Chatterjee DJ, Li WY, Parimoo D, Jeffers S, et al. Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors. Cancer Chemother Pharmacol 1999; 43: 489-96.
32. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-23.
33. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffle P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.
34. Dubey S, Schiller JH Three emerging new drugs for NSCLC: Pemetrexed, bortezomib, and cetuximab. Oncologist 2005; 10: 282-91.
35. Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW, et al. Phase I study of (6R)-5,10-dideazatetrahydrofolate: A folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 1993; 85: 1154-9.
36. Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, et al. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol 2000; 45: 103-10.
37. McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, et al. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res 2000; 6: 2677-84.
38. Bissett D, McLeod HL, Sheedy B, Collier M, Pithavala Y, Paradiso L, et al. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. Br J Cancer 2001; 84: 308-12.
39. Fontecave M, Atta M, Mulliez E. S-adenosylmethionine: Nothing goes to waste. Trends Biochem Sci 2004; 29: 243-9.
40. Sunden SL, Renduchintala MS, Park EI, Miklasz S, Garrow TA. Betaine-homocysteine melbyltransferase expression in porcine and human tissues and chromosomal localization of the human gene. Arch Biochem Biophys 1997; 345: 171-4.
41. Stipanuk MH. Sulfur amino acid metabolism: Pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr 2004; 24: 539-77
42. Kreis W. Tumor theraphy by deprivation of L-methionine: Rationale and results. Cancer Treat Rep 1979; 63: 1069-72.
43. Cellarier E, Durando X, Vasson MP, Farges MC, Demiden A, Maurizis JC, et al. Methionine dependency and cancer treatment. Cancer Treat Rev 2003; 29: 489-99.
44. Mecham JO, Rowitch D, Wallace CD, Stern PH, Hoffman RM. The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun 1983; 117:429-34.
45. Sekhon J, Pereira P, Sabbaghian N, Schievella AR, Rozen R. Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent tumour lines. Br J Cancer 2002; 87: 225-30.
46. Hoshiya, Guo H, Kubota T, Inada T, Asanuma F, Yamada Y, et al. Human tumors are methionine dependent in vivo. Anticancer Res 1995; 15: 717-8.
47. Nobori T, Szinai I, Amox D, Parker B, Olopade OI, Bucbhagen DL, et al. Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. Cancer Res 1993; 53: 1098-101.
48. Traweek ST, Riscoe MK, Ferro AJ, Braziel RM, Magenis RE, Fitchen JH. Methylthioadenosine phosphorylase deficiency in acute leukemia: pathologic, cytogenetic, and clinical features. Blood 1988; 71:1568-73.
49. Nobori T, Kurras JG, Della Ragione F, Waltz TA, Chen PP, Carson DA. Absence of methylthioadenosine phosphorylase in human gliomas. Cancer Res 1991; 51: 3193-7.
50. Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 2002; 12: 615-26.
51. Judde Ju, Ellis M, Frost P. Biochemical analysis of the role of transmethylation in the methionine dependence of tumor cells. Cancer Res 1989; 49: 4859-65.
52. Stern PH, Hoffman RM. Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro 1984; 20: 663-70.
53. Sugimura, T, Birnbaum SM, Winitz M, Greenstein JP. Quantitative nutritional studies with water-soluble, chemically defined diets. VI-II. The forced feeding of diets each lacking in one essential amino acid. Arch Biochem Biophys 1959; 81: 448-55.
54. Guo H, Lishko VK, Herrera H, Groce A. Kubota T, Hoffman RM. Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res 1993; 53: 5676-9.
55. Goseki N, Yamazaki S, Shimojyu K, Kando F, Marayama M, Endo M, et al. Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer a randomized, prospective clinical trial. Jpn J Cancer Res 1995; 86: 484-9.
56. Goseki N, Endo M, Onodera T, Kosaki G. Anti-tumor effect of L-methionine-deprived total parenteral nutrition with 5-fluorouracil administration on Yoshida sarcoma-bearing rats. Ann Surg 1991; 214: 83-8.
57. Hoshiya Y, Kubota T, Inada T, Kitajima M, Hoffman RM. Methionine-depletion modulates the efficacy of 5-fluorouracil in human gastric cancer in nude mice. Anticancer Res 1997; 17: 4371-5.
58. Poirson-Bichat F, Gonfalone G, Bras-Goncalves RA, Dutrillaux B, Poupon MF. Growth of methionine-dependent human prostate cancer (PC-3) is inhibited by ethionine combined with methionine starvation. Br J Cancer 1997; 75: 1605-42.
59. Poirson-Bichat F, Lopez R, Bras Goncalves RA, Miccoli L, Bourgeois Y, Demerseman P, et al. Methionine deprivation and methionine analogs inhibit cell proliferation and growth of human xenografted gliomas. Life Sci 1997; 60:919-31.
60. Porter CW, Suffin JR, Keith DD. Growth inhibition by methionine analog inhibitors of S-adenosylmethionine biosynthesis in the absence of polyamine depletion. Biochem Biophys Res Commun 1984; 122: 350-7.
61. Porter CW, Suffin JR. Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy. Anticancer Res 1986; 6: 525-42
62. Breillout F, Poupon MF, Blanchard P, Lascaux V, Echinard-Garin P, Robert-Gero M. Association of SIBA treatment and a Met-depleted diet inhibits in vitro growth and in vivo metastatic spread of experimental tumor cell lines. Clin Exp Metastasis 1988; 6: 3-16.
63. Tan Y, Xu M, Tan X, Tan X, Wang Y, Saikawa Y, et al. Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptometane-lyase for novel anticancer therapy. Protein Expr Purif 1997; 9: 233-45.
64. Yoshioka T, Wada T, Uchida N, Maki H, Yoshida H, Ide N, et al. Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res 1998; 58: 2583-7.
65. Tan Y, Xu M, Guo H, Sun X, Kubota T, Hoffman RM. Anticancer efficacy of methioninase in vivo. Anticancer Res 1996; 16: 3931-6.
66. Machover D, Zittoun J, Broet P, Metzger G, Orrico M, Goldschmidt E, et al. Cytotoxic synergism of methioninase in combination with 5-fluorouracil and folinic acid. Biochem Pharmacol 2001; 61: 867-76
67. Kokkinakis DM, Hoffman RM, Frenkel EP, Wick JB, Han Q, Xu M, et al. Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 2001; 61: 4017-23.
68. Tan Y, Sun X, Xu M, Tan X, Sasson A, Rashidi B, et al. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res 1999; 5: 2157-63.
69. Yang Z, Wang J. Yoshioka T, Li B, Lu Q, Li S, et al. Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. Clin Cancer Res 2004; 10: 2131-8.
70. Pavillard V, Drbal AA, Swame DJ, Phillips RM, Double JA, Nicolaou A. Analysis of cell-cycle kinetics and sulfur amino acid metabolism in methionine-dependent tumor cell lines; the effect of homocysteine supplementation. Biochem Pharmacol 2004; 67: 1587-99.
71. Stern PH, Hoffman RM. Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 1986; 76: 629-39.
72. Costello JF, Plass U. Methylation matters. J Med Genet 2001; 38: 285-303.
73. Moggs JG, Goodman JI, Trosko JE, Roberts RA. Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol Appl Pharmacol 2004; 196: 422-30.
74. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92
75. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
76. Shen L, Issa JP. Epigenetics in colorectal cancer. Curr Opin Gastroenterol 2002; 18: 68-73.
77. Lee PJ, Washer LL, Law DJ, Boland CR, Horonn IL, Feinberg AP. Limited up-regulation of DNA methyltransferase in human colon cancer reflecting increased cell proliferation. Proc Natl Acad Sci USA 1996; 93: 10366-70.
78. Schmidt WM, Sedivy R, Forstner B, Steger GG, Zochbauer-Muller S, Mader RM. Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence. Mol Carcinog 2007; 46: 766-72.
79. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol 2002; 13: 1699-716.
80. Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005; 65: 6305-11.
81. Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, et al. Zebularine: A unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci 2005; 1058: 246-54
82. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 2005; 11: 3862-8.
83. Villar-Garea A, Fraga MF, Espada J. Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 2003; 63: 4984-9.
84. Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 2005; 280: 40749-56
85. Fowler B. Genetic defects of folate and cobalamin metabolism. Eur J Pediatr 1998; 157(Suppl 2): S60-6.
86. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: Clinical consequences. Am J Pharmacogenomics 2001; 1: 189-201.
87. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002; 99: 5606-11.
88. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrathydrofolates in red blood cells. Proc Natl Acad Sci USA 1998; 95: 13217-20.
89. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611-5.
90. Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14: 785-92.
91. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365-9.
92. Stankova J, Shang J, Rozen R. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo. Clin Cancer Res 2005; 11: 2047-52.
93. Berg RW, Werner Ferguson PJ, Postenka C, Vincent Koropatnick DJ, et al. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase. J Pharmacol Exp Ther 2001; 298: 477-84.
94. Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 2001; 7:3613-24.
95. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 2001; 298: 934-40.
96. Chen Z, Schwahn BC, Wu Q, He X, Rozen R. Postnatal cerebellar defects in mice deficient in methylenetetrahydrofolate reductase. Int J Dev Neurosci 2005; 23: 465-74.
97. Kruman, II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20: 6920-6.
98. Mangiagalli A, Samuele A, Armentero MT, Bazzini E, Nappi G, Blandini F. Effects of homocysteine on apoptosis-related proteins and anti-oxidant systems in isolated human lymphocytes. Eur J Biochem, 2004; 271: 1671-6.